We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
(-7.6%)
Cap. Flow
+$275M
Cap. Flow
% of AUM
2.78%
Top 10 Holdings %
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$123M |
| 2 |
Neuropace
NPCE
|
+$93.1M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$77.8M |
| 4 |
Janux Therapeutics
JANX
|
+$77.2M |
| 5 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$74.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$94.6M |
| 2 |
AbCellera Biologics
ABCL
|
+$54.5M |
| 3 |
ADVM
Adverum Biotechnologies
ADVM
|
+$54.2M |
| 4 |
Molina Healthcare
MOH
|
+$38M |
| 5 |
PAND
Pandion Therapeutics Inc. Common Stock
PAND
|
+$31.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.72% |
| 2 | Miscellaneous | 4.15% |
| 3 | Technology | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neurocrine Biosciences
NBIX
$15.7B
| $120M | 1.21% |
1,231,115
-70,600
| -5% | -$6.77M |
|
27
Xtant Medical Holdings
XTNT
$53.9M
| $119M | 1.2% |
72,873,494
| – | – |
|
28
Edwards Lifesciences
EW
$52B
| $117M | 1.18% |
1,126,400
| – | – |
|
|
RPTX
29
DELISTED
Repare Therapeutics
RPTX
| $107M | 1.08% |
3,426,325
| – | – |
|
|
GRCL
30
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $103M | 1.04% |
7,884,870
| – | – |
|
|
31
Neuropace
NPCE
$495M
| $95.5M | 0.97% |
+4,012,281
| New | +$93.1M |
|
|
AFIB
32
DELISTED
Acutus Medical Inc
AFIB
| $93M | 0.94% |
5,477,958
| – | – |
|
33
Passage Bio
PASG
$14.5M
| $92.2M | 0.93% |
348,145
| – | – |
|
|
KNTE
34
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $89.6M | 0.91% |
3,847,929
| – | – |
|
35
Stryker
SYK
$127B
| $87.6M | 0.89% |
337,400
| – | – |
|
|
36
Janux Therapeutics
JANX
$1.1B
| $86.5M | 0.87% |
+3,466,386
| New | +$77.2M |
|
|
IMGN
37
DELISTED
Immunogen Inc
IMGN
| $85.3M | 0.86% |
12,936,622
+3,804,800
| +42% | +$26.5M |
|
38
CRISPR Therapeutics
CRSP
$5.58B
| $84M | 0.85% |
519,000
-33,500
| -6% | -$4.07M |
|
39
Progyny
PGNY
$1.99B
| $80.6M | 0.81% |
1,365,445
-559,815
| -29% | -$31.4M |
|
40
Aurinia Pharmaceuticals
AUPH
$2.17B
| $78.7M | 0.8% |
6,069,032
| – | – |
|
|
OSH
41
DELISTED
Oak Street Health, Inc.
OSH
| $77.8M | 0.79% |
1,328,300
+361,300
| +37% | +$21.5M |
|
|
SVA
42
DELISTED
Sinovac Biotech, Ltd
SVA
| $76.8M | 0.78% |
2,839,500
| – | – |
|
43
Adicet Bio
ACET
$84.8M
| $74.4M | 0.75% |
452,054
| – | – |
|
44
Keros Therapeutics
KROS
$219M
| $71.3M | 0.72% |
1,679,417
| – | – |
|
|
ETNB
45
DELISTED
89bio
ETNB
| $69.7M | 0.71% |
3,729,442
| – | – |
|
46
Theravance Biopharma
TBPH
$885M
| $66.3M | 0.67% |
4,564,045
-1,655,065
| -27% | -$31.1M |
|
47
MeiraGTx Holdings
MGTX
$1.33B
| $63.6M | 0.64% |
4,102,925
| – | – |
|
|
VECT
48
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $59.7M | 0.6% |
+5,123,304
| New | +$77.8M |
|
49
Ascendis Pharma A/S
ASND
$16.3B
| $58.9M | 0.6% |
447,859
-57,300
| -11% | -$7.64M |
|
50
Crinetics Pharmaceuticals
CRNX
$9B
| $56.5M | 0.57% |
2,996,876
+243,309
| +9% | +$4.28M |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2021 Portfolio in Review
As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.
- OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
- OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
- OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
- OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
- OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
- OrbiMed opened 24 new positions and closed 24 in Q2 2021.
- OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.
Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.